ASRNL:EURONEXT AMSTERDAMASR Nederland N.V. Analysis

The stock is trading at €66.4, comfortably above its 20‑day SMA of €65.35 and the 50‑day SMA of €62.20, signaling short‑term momentum. A 30‑day volatility of roughly 15% combined with a low beta (≈0.33) suggests modest price swings relative to the broader market. The RSI at 61 points to continued buying pressure without being overbought. While the MACD histogram is slightly negative, the overall trend remains bullish as indicated by the rising SMA hierarchy. Trading volume has been increasing, reinforcing the strength of the current move.
On the fundamentals side, revenue grew 9.5% year‑over‑year to €17.1 bn, supported by a solid gross margin of 52% and operating margin of 35%. The trailing PE of 30.7 sits well above the industry average of 16.7, but a forward PE of 10.6 reflects strong earnings expectations. The dividend yield of 5.14% is attractive, yet the payout ratio of 149% raises sustainability concerns. With €92.3 bn in cash versus €24.2 bn of debt, the balance sheet is cash‑rich, though operating cash flow remains negative. The DCF‑derived fair value of €421 implies a substantial undervaluation, translating to a modest upside of about 3.5% based on current pricing. Analysts (15) rate the stock as a “buy” with a median target of €69.5, reinforcing the positive outlook. The company’s diversified insurance and asset‑management platform, together with a low geographic concentration in the Netherlands, mitigates sector‑specific risks.